Kyntra Bio
KYNB
210 hedge funds and large institutions have $2.25B invested in Kyntra Bio in 2019 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 61 increasing their positions, 68 reducing their positions, and 19 closing their positions.
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
27% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $23.3M
11% more funds holding
Funds holding: 190 → 210 (+20)
0.05% less ownership
Funds ownership: 2.85% → 2.8% (-0.05%)
10% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 68
19% less capital invested
Capital invested by funds: $2.77B → $2.25B (-$520M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$34.2M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$19.2M |
| 3 |
BlackRock
New York
|
+$15.1M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$13.9M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.4M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$32.3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$30.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$13.4M |
KYNB Hedge Fund Activity: Q3 2019 in Review
210 of the 4,573 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2019, worth a combined $2.25B — down 19% from $2.77B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new KYNB positions and 19 closed out — a net gain of 20 holders — while 61 added to existing stakes and 68 trimmed.
The largest buyer was HHLR Advisors, adding an estimated $34.2M. The largest seller was Fidelity Investments, cutting an estimated $37.4M.
- 210 institutional investors held Kyntra Bio (KYNB) as of Q3 2019, up from 190 in Q2 2019.
- Funds reported $2.25B of Kyntra Bio stock for Q3 2019, down 19% quarter-over-quarter.
- 39 funds opened new Kyntra Bio positions in Q3 2019 and 19 closed out, a net change of +20 holders.
- The largest Kyntra Bio buyer in Q3 2019 was HHLR Advisors, an estimated $34.2M added.
- The largest Kyntra Bio seller in Q3 2019 was Fidelity Investments, an estimated $37.4M sold.
Based on aggregated 13F filings for Q3 2019.